ES2313777T3 - Inhibidores de la neovascularizacion. - Google Patents

Inhibidores de la neovascularizacion. Download PDF

Info

Publication number: ES2313777T3
Authority: ES; Spain
Prior art keywords: hgf; baselineskip; neovascularization; polypeptide; cells
Prior art date: 1998-04-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES99912129T

Other languages

English (en)

Spanish (es)

Inventor

Toshikazu Nakamura

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-28

Filing date

1999-04-06

Publication date

2009-03-01

1999-04-06 Application filed by Individual filed Critical Individual

2009-03-01 Application granted granted Critical

2009-03-01 Publication of ES2313777T3 publication Critical patent/ES2313777T3/es

2019-04-06 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

206010029113 Neovascularisation Diseases 0.000 title claims abstract description 31
239000003112 inhibitor Substances 0.000 title description 9
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 56
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 53
229920001184 polypeptide Polymers 0.000 claims abstract description 51
230000002401 inhibitory effect Effects 0.000 claims abstract description 25
239000004037 angiogenesis inhibitor Substances 0.000 claims abstract description 21
239000004480 active ingredient Substances 0.000 claims abstract description 6
230000009471 action Effects 0.000 claims description 28
230000003042 antagnostic effect Effects 0.000 claims description 11
102000027430 HGF receptors Human genes 0.000 claims description 10
108091008603 HGF receptors Proteins 0.000 claims description 10
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 7
230000001404 mediated effect Effects 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 4
101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims description 3
102100021866 Hepatocyte growth factor Human genes 0.000 claims description 2
108090000100 Hepatocyte Growth Factor Proteins 0.000 abstract description 271
102000003745 Hepatocyte Growth Factor Human genes 0.000 abstract description 269
230000000694 effects Effects 0.000 abstract description 26
150000001413 amino acids Chemical class 0.000 abstract description 19
125000003275 alpha amino acid group Chemical group 0.000 abstract description 15
201000010099 disease Diseases 0.000 abstract description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 14
238000007792 addition Methods 0.000 abstract description 11
238000006467 substitution reaction Methods 0.000 abstract description 3
230000008485 antagonism Effects 0.000 abstract 1
230000037430 deletion Effects 0.000 abstract 1
238000012217 deletion Methods 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 32
206010028980 Neoplasm Diseases 0.000 description 29
241000282414 Homo sapiens Species 0.000 description 22
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
238000000034 method Methods 0.000 description 21
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 19
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 19
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 19
239000012634 fragment Substances 0.000 description 18
230000012010 growth Effects 0.000 description 18
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 17
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 17
210000002889 endothelial cell Anatomy 0.000 description 17
206010027476 Metastases Diseases 0.000 description 14
238000010586 diagram Methods 0.000 description 14
230000002297 mitogenic effect Effects 0.000 description 14
239000000243 solution Substances 0.000 description 14
230000009401 metastasis Effects 0.000 description 13
238000006366 phosphorylation reaction Methods 0.000 description 13
239000011780 sodium chloride Substances 0.000 description 13
210000004072 lung Anatomy 0.000 description 12
230000026731 phosphorylation Effects 0.000 description 12
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 11
239000000203 mixture Substances 0.000 description 11
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 11
230000000921 morphogenic effect Effects 0.000 description 9
238000002360 preparation method Methods 0.000 description 9
108090000623 proteins and genes Proteins 0.000 description 9
102000016387 Pancreatic elastase Human genes 0.000 description 8
108010067372 Pancreatic elastase Proteins 0.000 description 8
210000003494 hepatocyte Anatomy 0.000 description 8
239000002609 medium Substances 0.000 description 8
210000004379 membrane Anatomy 0.000 description 8
239000012528 membrane Substances 0.000 description 8
102000005962 receptors Human genes 0.000 description 8
108020003175 receptors Proteins 0.000 description 8
239000003826 tablet Substances 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
229920002472 Starch Polymers 0.000 description 7
230000010261 cell growth Effects 0.000 description 7
210000004185 liver Anatomy 0.000 description 7
230000001394 metastastic effect Effects 0.000 description 7
206010061289 metastatic neoplasm Diseases 0.000 description 7
239000008107 starch Substances 0.000 description 7
235000019698 starch Nutrition 0.000 description 7
230000000638 stimulation Effects 0.000 description 7
230000002792 vascular Effects 0.000 description 7
210000003556 vascular endothelial cell Anatomy 0.000 description 7
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 6
108010010803 Gelatin Proteins 0.000 description 6
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
239000008273 gelatin Substances 0.000 description 6
229920000159 gelatin Polymers 0.000 description 6
235000019322 gelatine Nutrition 0.000 description 6
235000011852 gelatine desserts Nutrition 0.000 description 6
239000008103 glucose Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
208000020816 lung neoplasm Diseases 0.000 description 6
229940043131 pyroglutamate Drugs 0.000 description 6
108010047303 von Willebrand Factor Proteins 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 5
230000006820 DNA synthesis Effects 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
201000011510 cancer Diseases 0.000 description 5
230000003511 endothelial effect Effects 0.000 description 5
239000003102 growth factor Substances 0.000 description 5
210000004088 microvessel Anatomy 0.000 description 5
210000004897 n-terminal region Anatomy 0.000 description 5
239000002674 ointment Substances 0.000 description 5
239000000843 powder Substances 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
239000002904 solvent Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
238000011282 treatment Methods 0.000 description 5
239000003981 vehicle Substances 0.000 description 5
102100036537 von Willebrand factor Human genes 0.000 description 5
229960001134 von willebrand factor Drugs 0.000 description 5
108010001857 Cell Surface Receptors Proteins 0.000 description 4
206010012689 Diabetic retinopathy Diseases 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
206010038933 Retinopathy of prematurity Diseases 0.000 description 4
230000002159 abnormal effect Effects 0.000 description 4
206010064930 age-related macular degeneration Diseases 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
239000012091 fetal bovine serum Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
238000001502 gel electrophoresis Methods 0.000 description 4
238000010353 genetic engineering Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
230000009545 invasion Effects 0.000 description 4
239000008101 lactose Substances 0.000 description 4
102000006240 membrane receptors Human genes 0.000 description 4
230000005012 migration Effects 0.000 description 4
238000013508 migration Methods 0.000 description 4
230000001181 motogenic effect Effects 0.000 description 4
230000037023 motor activity Effects 0.000 description 4
239000012071 phase Substances 0.000 description 4
230000008569 process Effects 0.000 description 4
239000000047 product Substances 0.000 description 4
230000002685 pulmonary effect Effects 0.000 description 4
230000002441 reversible effect Effects 0.000 description 4
206010039073 rheumatoid arthritis Diseases 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 3
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
239000005995 Aluminium silicate Substances 0.000 description 3
206010006187 Breast cancer Diseases 0.000 description 3
208000026310 Breast neoplasm Diseases 0.000 description 3
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
241000287828 Gallus gallus Species 0.000 description 3
206010058467 Lung neoplasm malignant Diseases 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
241000699660 Mus musculus Species 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
206010052428 Wound Diseases 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
235000012211 aluminium silicate Nutrition 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
239000002775 capsule Substances 0.000 description 3
210000000170 cell membrane Anatomy 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
229940110456 cocoa butter Drugs 0.000 description 3
235000019868 cocoa butter Nutrition 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
230000008030 elimination Effects 0.000 description 3
238000003379 elimination reaction Methods 0.000 description 3
210000002919 epithelial cell Anatomy 0.000 description 3
206010020718 hyperplasia Diseases 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
239000007791 liquid phase Substances 0.000 description 3
201000005202 lung cancer Diseases 0.000 description 3
208000037841 lung tumor Diseases 0.000 description 3
210000004925 microvascular endothelial cell Anatomy 0.000 description 3
238000011580 nude mouse model Methods 0.000 description 3
230000003204 osmotic effect Effects 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
230000002335 preservative effect Effects 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Polymers OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 2
JNYAEWCLZODPBN-UHFFFAOYSA-N 2-(1,2-dihydroxyethyl)oxolane-3,4-diol Polymers OCC(O)C1OCC(O)C1O JNYAEWCLZODPBN-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
101150022655 HGF gene Proteins 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000008272 agar Substances 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
230000033115 angiogenesis Effects 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000000711 cancerogenic effect Effects 0.000 description 2
230000012292 cell migration Effects 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
230000010595 endothelial cell migration Effects 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
230000007515 enzymatic degradation Effects 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
-1 fatty acid esters Chemical class 0.000 description 2
230000006870 function Effects 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
239000008187 granular material Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
230000002055 immunohistochemical effect Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
239000003226 mitogen Substances 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
238000010647 peptide synthesis reaction Methods 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
239000006187 pill Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920001296 polysiloxane Polymers 0.000 description 2
229940043274 prophylactic drug Drugs 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
JNYAEWCLZODPBN-CTQIIAAMSA-N sorbitan Polymers OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
210000005166 vasculature Anatomy 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
230000029663 wound healing Effects 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
208000003120 Angiofibroma Diseases 0.000 description 1
102400000068 Angiostatin Human genes 0.000 description 1
108010079709 Angiostatins Proteins 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
208000003732 Cat-scratch disease Diseases 0.000 description 1
206010011017 Corneal graft rejection Diseases 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
102400001368 Epidermal growth factor Human genes 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
102100037362 Fibronectin Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
241000282412 Homo Species 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
208000002260 Keloid Diseases 0.000 description 1
206010023330 Keloid scar Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
201000004404 Neurofibroma Diseases 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
108090000919 Pyroglutamyl-Peptidase I Proteins 0.000 description 1
229920000297 Rayon Polymers 0.000 description 1
101100112995 Schizosaccharomyces pombe (strain 972 / ATCC 24843) sim4 gene Proteins 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
102000012479 Serine Proteases Human genes 0.000 description 1
108010022999 Serine Proteases Proteins 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
206010043189 Telangiectasia Diseases 0.000 description 1
108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
208000014070 Vestibular schwannoma Diseases 0.000 description 1
101100020289 Xenopus laevis koza gene Proteins 0.000 description 1
229940124532 absorption promoter Drugs 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
208000004064 acoustic neuroma Diseases 0.000 description 1
235000016127 added sugars Nutrition 0.000 description 1
239000002390 adhesive tape Substances 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
230000002491 angiogenic effect Effects 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
230000001621 anti-mitogenic effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
238000009933 burial Methods 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
231100000357 carcinogen Toxicity 0.000 description 1
231100000315 carcinogenic Toxicity 0.000 description 1
239000003183 carcinogenic agent Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
210000003711 chorioallantoic membrane Anatomy 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000000512 collagen gel Substances 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000002900 effect on cell Effects 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
210000003278 egg shell Anatomy 0.000 description 1
210000000969 egg white Anatomy 0.000 description 1
235000014103 egg white Nutrition 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000003885 eye ointment Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000000835 fiber Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
201000010175 gallbladder cancer Diseases 0.000 description 1
239000000499 gel Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
125000000404 glutamine group Chemical class N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
230000009422 growth inhibiting effect Effects 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
201000011066 hemangioma Diseases 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
102000057308 human HGF Human genes 0.000 description 1
239000003906 humectant Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
201000001371 inclusion conjunctivitis Diseases 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002700 inhibitory effect on cancer Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
239000008274 jelly Substances 0.000 description 1
210000001117 keloid Anatomy 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
210000005228 liver tissue Anatomy 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
230000029849 luteinization Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
230000035772 mutation Effects 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
201000003142 neovascular glaucoma Diseases 0.000 description 1
108010065444 neurokinin receptor 4 Proteins 0.000 description 1
239000004745 nonwoven fabric Substances 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
210000004738 parenchymal cell Anatomy 0.000 description 1
239000004031 partial agonist Substances 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000011148 porous material Substances 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
239000002964 rayon Substances 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000009711 regulatory function Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
210000000998 shell membrane Anatomy 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000020374 simple syrup Nutrition 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000007940 sugar coated tablet Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
208000009056 telangiectasis Diseases 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
229960001479 tosylchloramide sodium Drugs 0.000 description 1
206010044325 trachoma Diseases 0.000 description 1
238000001890 transfection Methods 0.000 description 1
108010002164 tyrosine receptor Proteins 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
210000000264 venule Anatomy 0.000 description 1
239000003643 water by type Substances 0.000 description 1
238000001262 western blot Methods 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1
239000002759 woven fabric Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ES99912129T 1998-04-28 1999-04-06 Inhibidores de la neovascularizacion. Expired - Lifetime ES2313777T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP10-134681		1998-04-28
JP13468198		1998-04-28

Publications (1)

Publication Number	Publication Date
ES2313777T3 true ES2313777T3 (es)	2009-03-01

Family

ID=15134093

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES99912129T Expired - Lifetime ES2313777T3 (es)	1998-04-28	1999-04-06	Inhibidores de la neovascularizacion.

Country Status (9)

Country	Link
US (1)	US20090023658A1 (da)
EP (1)	EP1074264B1 (da)
JP (1)	JP4094814B2 (da)
AT (1)	ATE408415T1 (da)
CA (1)	CA2327382C (da)
DE (1)	DE69939586D1 (da)
DK (1)	DK1074264T3 (da)
ES (1)	ES2313777T3 (da)
WO (1)	WO1999055361A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1320384B1 (en)	2000-08-28	2007-10-10	Damavand Wound AB	The synergetic effects of hgf and antibacterial treatment
US20030118585A1 (en)	2001-10-17	2003-06-26	Agy Therapeutics	Use of protein biomolecular targets in the treatment and visualization of brain tumors
FR2831540B1 (fr) *	2001-10-31	2004-07-09	Inst Vaisseaux Et Du Sang	Peptide isole du facteur de croissance hepatocytaire et ses variants, procede de preparation et utilisation en therapeutique en tant qu'agents antiangiogeniques
JP2003250549A (ja) *	2002-02-25	2003-09-09	Kringle Pharma Inc	Ｎｋ４遺伝子または組換えｎｋ４蛋白質からなる医薬
AU2003270118A1 (en) *	2002-08-30	2004-03-19	F. Hoffmann-La Roche Ag	Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
JP4716741B2 (ja) *	2004-01-27	2011-07-06	敏一中村	糖鎖欠損型ＨＧＦα鎖部分蛋白質
WO2009125831A1 (ja) *	2008-04-11	2009-10-15	有限会社スリーピー	Ｎｋ４に対するモノクローナル抗体
SG10201912684TA (en) *	2015-06-25	2020-03-30	Taiho Pharmaceutical Co Ltd	Therapeutic agent for fibrosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69133492T2 (de) *	1990-06-11	2006-08-10	Nakamura, Toshikazu	Rekombinanter menschlicher Hepatozytwachstumsfaktor und Verfahren zu seiner Herstellung
US6566098B1 (en) *	1990-09-14	2003-05-20	The United States Of America As Represented By The Department Of Health And Human Services	DNA encoding truncated hepatocyte growth factor variants
ATE355379T1 (de) *	1994-04-26	2006-03-15	Childrens Medical Center	Angiostatin und verfahren zu seiner nutzung zur vermeidung der angiogenese
NZ307044A (en) *	1995-04-26	2002-03-01	Childrens Medical Center	Angiostatin fragments with antiangiogenic activity
US5686292A (en) *	1995-06-02	1997-11-11	Genentech, Inc.	Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6855685B2 (en) *	1995-10-24	2005-02-15	Toshikazu Nakamura	Anti-cancer agent
JP2003250549A (ja) *	2002-02-25	2003-09-09	Kringle Pharma Inc	Ｎｋ４遺伝子または組換えｎｋ４蛋白質からなる医薬

1999
- 1999-04-06 DE DE69939586T patent/DE69939586D1/de not_active Expired - Lifetime
- 1999-04-06 JP JP2000545559A patent/JP4094814B2/ja not_active Expired - Fee Related
- 1999-04-06 WO PCT/JP1999/001834 patent/WO1999055361A1/ja not_active Ceased
- 1999-04-06 DK DK99912129T patent/DK1074264T3/da active
- 1999-04-06 EP EP99912129A patent/EP1074264B1/en not_active Expired - Lifetime
- 1999-04-06 AT AT99912129T patent/ATE408415T1/de active
- 1999-04-06 ES ES99912129T patent/ES2313777T3/es not_active Expired - Lifetime
- 1999-04-06 CA CA2327382A patent/CA2327382C/en not_active Expired - Fee Related
2008
- 2008-08-05 US US12/186,261 patent/US20090023658A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ATE408415T1 (de)	2008-10-15
EP1074264B1 (en)	2008-09-17
CA2327382A1 (en)	1999-11-04
WO1999055361A1 (en)	1999-11-04
DE69939586D1 (de)	2008-10-30
DK1074264T3 (da)	2008-11-24
EP1074264A1 (en)	2001-02-07
US20090023658A1 (en)	2009-01-22
CA2327382C (en)	2012-12-18
JP4094814B2 (ja)	2008-06-04
EP1074264A4 (en)	2004-11-10

Publication	Publication Date	Title
Folkman et al.	1991	Duodenal ulcer. Discovery of a new mechanism and development of angiogenic therapy that accelerates healing
Maehara et al.	2001	NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells
JP5905833B2 (ja)	2016-04-20	心筋虚血−再潅流障害の予防、処置または遅延のための、ニューレグリンを含む組成物およびその利用
BRPI0512286B1 (pt)	2020-03-24	Proteínas quiméricas inibidoras da angiogênese e o uso
JP2007051150A (ja)	2007-03-01	結合組織増殖因子
US20090023658A1 (en)	2009-01-22	Neovascularization Inhibitors Derived From HGF and Methods Involving the Same
CN112386678B (zh)	2023-07-07	多肽或其衍生物的应用
WO2011119009A2 (en)	2011-09-29	Peptides for promoting angiogenesis and an use thereof
US7696160B2 (en)	2010-04-13	Compositions useful for and methods of modulating angiogenesis
ES2330918T3 (es)	2009-12-17	Inhibidor del activador del factor de crecimiento de hepatocitos para usar en la modulacion de la angiogenesis y la cardiovascularizacion.
KR100335348B1 (ko)	2002-05-06	종양 혈관신생 억제기능을 가지는 살모신을 유효성분으로 함유하는 항암제
JPWO1999055361A1 (ja)	2002-11-05	血管新生抑制剤
ES2235200T3 (es)	2005-07-01	Mutante de hgf y su uso como agente anticanceroso.
CA2304956C (en)	2013-12-03	Pharmaceutical composition for preventing or treating ischemic diseases
US20030004110A1 (en)	2003-01-02	Therapeutic compositions and methods for enhancing angiogenesis
US20190255144A1 (en)	2019-08-22	Specific oligopeptides as anti-angiogenic drugs
US7507401B2 (en)	2009-03-24	Anti-cancer agent
CN101015683B (zh)	2010-07-21	人rtn4b蛋白在制备创伤愈合药物中的应用
KR101228668B1 (ko)	2013-01-31	혈관신생 억제 활성을 갖는 펩타이드 및 이의 용도
US8106009B2 (en)	2012-01-31	Pharmaceutical composition for preventing or treating ischemic diseases
AU2003200309B2 (en)	2005-08-18	Pharmaceutical Composition for Preventing or Treating Ischaemic Diseases
HK40047414B (en)	2023-09-01	Application of polypeptide or derivative thereof
Elamaa	2004	Type XVIII collagen: characterization of the primary structure and expression pattern of different variants in Xenopus laevis, characterization of the human gene structure and analysis of transgenic mice expressing endostatin
EP1495766A1 (en)	2005-01-12	Factor VII activating protease (FSAP) derived polypeptides for the treatment of angiogenesis-related disorders